Subsidiaries of KPS
Full menu
About KPS
Investor Relations
Subsidiaries of KPS
BIXINK
BIXINK THERAPEUTICS is a new biopharmaceutical company aiming to develop a new treatment paradigm with creativity and innovation.
The global market for therapeutic agents, which has grown focusing on drugs based on chemical compounds, is accelerating its pace of development through a wide range of advanced technologies. In line with the trend, we aim to become a company providing the source of a “healthier life” through the development and convergence of technologies spanning across the times. We will do our best to achieve social value through the convergence of information technology and biotechnology, and to develop into an innovative pharmaceutical company not only on a domestic level but also on a global stage.
We ask for your encouragement and support for our new start toward creative transformation.
Overview
| Date of foundation 2016.08.11 | 2016.08.11 |
|---|---|
| Name of CEO(s) | Name of CEO(s) Ha-yong Kim, Mi-hyeong Han (Respective representation) |
| No. of Employees (As of 2018) | 23 (As of December 31, 2021) |
| Paid-in capital | Paid-in capital 4.41 billion won |
| Main Business | Anticancer drugs and adjuvant therapies/digital therapeutics |
| Tel | Geo-Young Co., Ltd., Dongwon Pharmaceutical Wholesale Co., Ltd. |
| Address | 5th floor, Bangbang Building, 292, Gangnamdae-ro, Gangnam-gu, Seoul (Dogok-ro) |
| Licenses, etc. |
- |
History
| October 21, 2021 | · Approval for domestic marketing and sales of ‘Neratinib’ (Nerlynx Tab.), an adjuvant therapy for breast cancer |
|---|---|
| April 25, 2021 | · Started a US clinical trial of ‘OC Free’, the first digital therapeutics in Korea |
| December 18, 2020 | · Acquired Asian distribution rights for ‘Mucosamin’, a preventive and therapeutic agent for mucositis and dermatitis with Italian pharmaceutical company PDI (Professional Dietetics International) (Exclusive sales rights in Korea and Japan, priority negotiation rights in 7 countries including Hong Kong and Malaysia) |
| October 25, 2020 | · Completed pre-IND submission of study protocol for a US clinical trial of ‘OC Free’, digital therapeutics |
| May 6, 2020 | · Invested $1 million in Limbix Health, Inc., a company specializing in the development of digital therapeutics in the US |
| May 6, 2020 | · KPS becomes the largest shareholder of BIXINK THERAPEUTICS (45.35% stake) |
| May 1, 2020 | · Signed a license agreement with US pharmaceutical company ‘Puma Biotechnology, Inc.’ for exclusive right for marketing ‘neratinib’ in Korea |
| January 20, 2020 | · Signed an agreement for development of basic digital education content on facility maintenance with Inha Technical College Industry-University Cooperation Foundation |
| December 22, 2019 | · Signed a contract to produce Da Vinci Learning Guide video with Chung-Ang University's University Innovation Support Project Group |
| October 15, 2019 | · Relocation of the main office (Room 303, 10, Dogok-ro 2-gil, Gangnam-gu, Seoul) |
| October 15, 2019 | · Change of the company name(Q Lab > BIXINK THERAPEUTICS) |
| October 5, 2019 | · Signed an agreement for development of online teaching method content with Center for Teaching & Learning of Seoul National University |
| July 15, 2019 | · Signed an agreement for development of K-MOOC video content with Center for Teaching & Learning of Chung-Ang University |
| September 27, 2017 | · Relocation of the main office (Room 1112, 305, Gangnam-daero, Seocho-gu, Seoul) |
| August 10, 2016 | · Foundation of Q Lab corporation(Room 388, 3rd floor, 11, Bongeunsa-ro 63-gil, Gangnam-gu, Seoul) |
